Evidence map›Paper›PMID 39466906›Full record

ArticleJournal of medical virology2024

Comparative Analysis of 2022 Outbreak MPXV and Previous Clade II MPXV.

Joseph Patrick McGrail, Alberto Paniz Mondolfi, Juan David Ramírez, Santiago Vidal, Adolfo García-Sastre, Gustavo Palacios, Mari Paz Sanchez-Seco, Susana Guerra

Abstract readComparative Study
In one paragraph

Article in Journal of medical virology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Joseph Patrick McGrailDepartment of Preventive Medicine, Public Health and Microbiology, Universidad Autónoma de Madrid, Madrid, Spain.ORCID 0000-0002-2430-8806
Alberto Paniz MondolfiDepartment of Pathology, Molecular, and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.ORCID 0000-0003-1259-1736
Juan David RamírezDepartment of Pathology, Molecular, and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Santiago VidalDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, USA.ORCID 0000-0002-0105-4583
Adolfo García-SastreDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, USA.ORCID 0000-0002-6551-1827
Gustavo PalaciosDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, USA.ORCID 0000-0001-5062-1938
Mari Paz Sanchez-SecoCentro Nacional de Microbiología, Instituto de Salud Carlos III, Madrid, Spain.ORCID 0000-0001-9033-7704
Susana GuerraDepartment of Preventive Medicine, Public Health and Microbiology, Universidad Autónoma de Madrid, Madrid, Spain.ORCID 0000-0001-9067-2991

Funding

This study was supported by ISIDORe consortium, Agencia Estatal de Investigación and FEDER/FSE (PID2023-146351OB-I00, PID2020-117425RB-C21, PDC2021-121307-I00)
6 · The paper itself

Abstract

The 2022-2024 outbreak of MPOX is an important worldwide public health issue that has triggered significant concerns in the scientific community. MPOX is caused by monkeypox virus (MPXV) belonging to the Poxviridae family. The study of MPXV presents a multifaceted challenge due to the diverse viral formThis study was supported by ISIDORe consortium and Agencia Estatal de Investigación.s produced by this pathogen. Notably the intracellular mature viruses (MVs) primarily contribute to localized lesions and host-to-host transmission, while the extracellular enveloped viruses (EVs) are associated with systemic infection. Clinically, MPOX manifests as a vesiculopustular rash that initially emerges on the face and trunk, subsequently spreading throughout the body, with heightened severity observed in immunocompromised individuals. Results obtained in this manuscript indicate that the 2022 outbreak MPXV has a significantly slower viral cycle compared with previous Clade II strains, with WRAIR 7-61 being more intermediate and USA 2003 producing highest viral titers. Additionally, proteomic and phospho-proteomic analysis displays differences in protein expression between these three strains. These findings highlight key differences between the current Lineage B.1 MPXV and previous strains. Further studies will be undertaken to demonstrate if these differences are important for the apparent increased human-to-human transmission mechanisms observed in the Clade IIb MPXV outbreak.

Indexed as

Disease OutbreaksMonkeypox virusMpox, MonkeypoxGenome, ViralHumansPhylogenyClade IIEVMPOX diseaseMPXVMV

Identifiers

PMID39466906
PMCPMC11600476

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.